WAVEMAN · COMPANY

DNLI · Denali Therapeutics Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

DNLI

Name: Denali Therapeutics Inc. (DNLI) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Denali Therapeutics Inc.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001714899

FORM 144 · 3☆ WATCH

INSIDER NET · 180D

-$136.5K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

175

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$136.5K over 180 days

-$136.5K over 90 days

more than 53% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

175 funds added or opened last quarter

more than 83% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

10.9% of shares outstanding short · 12.1 days to cover · settled 2026-07-31

more than 80% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

3 insiders have filed intent to sell ($403.5K) and have not sold yet.

175 funds added or opened positions in the latest 13F quarter, of 294 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +47.6%

+47.6%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $136.5K sold by insiders over 180 days, 175 funds added last quarter, $403.5K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Denali Therapeutics Inc. insiders sold a net $136.5K of stock across 210 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Thornberry Nancy

Director

SELL

2026-09-02

10,824.0

$247.3K

Thornberry Nancy

Director

SELL

2026-09-02

615.0

$14.6K

Schuth Alexander O.

COFO and Secretary

SELL

2026-09-01

2,768.0

$64.9K

Schuth Alexander O.

COFO and Secretary

SELL

2026-08-11

2,857.0

$71.6K

Watts Ryan J.

President and CEO

SELL

2026-01-06

35,198.0

$580.8K

210 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 205 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

14,026,413.0 sh

$360.8M

BAILLIE GIFFORD & CO

11,960,230.0 sh

$307.6M

STATE STREET CORP

7,049,304.0 sh

$181.3M

Temasek Holdings (Private) Ltd

7,012,974.0 sh

$180.4M

VANGUARD PORTFOLIO MANAGEMENT LLC

6,477,057.0 sh

$166.6M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

NANCY THORNBERRY

FILED 2026-09-02

$266.1K

ALEXANDER SCHUTH

FILED 2026-09-01

$65.8K

Schuth Alexander O.

FILED 2026-08-11

$71.6K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

ALPS Medical Breakthroughs ETF

$2.8M POSITION · AS OF 2026-02-28

2.0%

DANA EPIPHANY SMALL CAP EQUITY FUND

$338.0K POSITION · AS OF 2026-04-30

1.0%

SBH SMALL CAP GROWTH FUND

$2.8M POSITION · AS OF 2026-03-31

0.9%

Virtus Biotech Clinical Trials Etf

$287.4K POSITION · AS OF 2026-04-30

0.8%

State Street(R) SPDR(R) S&P(R) Biotech ETF

$54.4M POSITION · AS OF 2026-03-31

0.7%

Baillie Gifford U.S. Equity Growth Fund

$111.0K POSITION · AS OF 2026-03-31

0.7%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 13 registered trials, 9 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

3 ACTIVE

Phase 2

1 ACTIVE

Not applicable

0 ACTIVE

Multi-phase

5 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Dr. Watts

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$4.8M

$1.1M

$4.0M

-80%

+25%

2024

$6.6M

$6.1M

$4.0M

-76%

-7%

2023

$7.9M

-$813.5K

$4.2M

-74%

-6%

2022

$9.3M

-$12.1M

$5.2M

-67%

-10%

2021

$12.7M

-$58.2M

$6.6M

-47%

+0%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$0	$0	$330.5M	$105.1M
OPERATING INCOME	$-555.3M	$-487.3M	$-196.7M	$-340.7M
NET INCOME	$-512.5M	$-422.8M	$-145.2M	$-326.0M
EPS (DILUTED)	-2.97	-2.57	-1.06	-2.60
OPERATING CASH FLOW	$-412.6M	$-347.7M	$-358.0M	$-244.7M
CASH	$205.3M	$175.0M	$127.1M	$218.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE